43183-16-0Relevant academic research and scientific papers
THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE
-
Page/Page column 24-25, (2009/10/01)
There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibi
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors
Nuti, Elisa,Panelli, Laura,Casalini, Francesca,Avramova, Stanislava I.,Orlandini, Elisabetta,Santamaria, Salvatore,Nencetti, Susanna,Tuccinardi, Tiziano,Martinelli, Adriano,Cercignani, Giovanni,D'Amelio, Nicola,Maiocchi, Alessandro,Uggeri, Fulvio,Rossello, Armando
experimental part, p. 6347 - 6361 (2010/03/24)
Overexpression of macrophage elastase (MMP-12), a member of the matrix metalloproteinases family, can be linked to tissue remodeling and degradation in some inflammatory processes, such as chronic obstructive pulmonary disease (COPD), emphysema, rheumatoi
INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE
-
Page/Page column 56-57, (2008/06/13)
There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibi
Nitrophenyl derivatives as aldose reductase inhibitors
Costantino, Luca,Ferrari, Anna Maria,Gamberini, Maria Cristina,Rastelli, Giulio
, p. 3923 - 3931 (2007/10/03)
Nitrophenyl derivatives were recently discovered as a new class of ALR2 inhibitors by means of docking and database screening of the National Cancer Institute database of organic molecules. The nitro group was predicted to bind to the Tyr48 and His110 act
Derivatives of hydroxyphenylsulfanylbenzoic and hydroxphenylsulfanylarylacetic acids
-
, (2008/06/13)
Processes for the preparation of derivatives of hydroxyphenylsulfanylbenzoic and hydroxyphenylsulfanylarylacetic acids of Formula (I) and pharmaceutical compositions including these compounds are provided: wherein X is H, halogen or NO2group, n is 0 or 1, and m is 2 to 4 if Z is either 4-acetyl-3 -hydroxy-2-propylphenoxy of Formula (II): or a piperazinyl residue, or m is 1 if Z is quinolin-2-yl or 6-chloroquinoli-2-yl.
